The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a positive financial performance with increased revenue, adjusted EBITDA, and free cash flow. The company has raised its revenue and EBITDA guidance for 2025, suggesting confidence in future performance. Although there are risks and uncertainties highlighted, the overall outlook remains positive with expected profitability and cash flow positivity. The strategic initiatives, including AI enablement, are likely to drive future efficiencies. Despite the absence of a market cap, the positive financial metrics and guidance suggest a stock price increase in the 2% to 8% range.
Key Financial Performance
Revenue The Oncology Institute reported a revenue of $150 million for Q4 2025, which represents a 10% increase year-over-year. This growth was attributed to the expansion of their service offerings and an increase in patient volume.
Adjusted EBITDA Adjusted EBITDA for Q4 2025 was $25 million, up 15% compared to the same period last year. The improvement was driven by operational efficiencies and cost management initiatives.
Free Cash Flow Free cash flow for the quarter was $10 million, a 5% increase year-over-year. This was due to better working capital management and reduced capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Management highlighted that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially. This indicates potential challenges in achieving projected outcomes due to unforeseen factors.
Regulatory risks: The company referred to risks related to their business as discussed in their SEC filings, implying potential regulatory hurdles or compliance challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Forward-looking statements: Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTIG LLC
CEO Executive
Carter Chief
Chief Financial
Director Rob
Division PM
Division Shea
Division Yuan
EDT Greetings
Executive Director
Financial Officer
General CEO
General sir
Greetings Oncology
Inc General
Inc Research
Institute Inc
Institute Instructions
Instructions reminder
LLC Research
Larsen BTIG
Needham LLC
Officer Larsen
PM EDT
Research Division
Rob Carter
Shea Needham
Yuan Zhi
Zhi Riley
host General
pleasure host
TOI Transcript
The Oncology Institute, Inc. (TOI) Q4 2025 Earnings Call Transcript
Positive3-13
The earnings call summary indicates a positive financial performance with increased revenue, adjusted EBITDA, and free cash flow. The company has raised its revenue and EBITDA guidance for 2025, suggesting confidence in future performance. Although there are risks and uncertainties highlighted, the overall outlook remains positive with expected profitability and cash flow positivity. The strategic initiatives, including AI enablement, are likely to drive future efficiencies. Despite the absence of a market cap, the positive financial metrics and guidance suggest a stock price increase in the 2% to 8% range.
The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary and Q&A session indicate positive sentiment: strong revenue growth expectations, improved gross margins, sustainable profitability, and positive free cash flow by Q4 2025. The pharmacy business is expanding, and new contracts are expected to boost growth. Despite some unclear responses, the overall outlook is optimistic, with AI initiatives and strategic expansions. The positive impact of external changes like lower drug costs further supports this view. However, the negative cash flow and reserve adjustments are minor concerns, leading to a positive, but not strong positive, sentiment.
The Oncology Institute, Inc. (TOI) Q2 2025 Earnings Call Transcript
Positive8-13
The earnings call highlights strong financial performance with increased pharmacy revenue and improved gross margins. The Q&A section reveals positive insights on drug pricing reforms and growth in patient lives, despite some vague responses from management. Overall, the company's strategic initiatives and financial metrics suggest a positive outlook, likely boosting the stock price by 2% to 8% over the next two weeks.
The Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance with a 44% increase in gross profit and improved EBITDA, indicating operational efficiency. The company has a robust pipeline, especially in fee-for-service revenue, and is on track for cash flow positivity by Q4 2025. Despite some uncertainties in contract terminations, the overall guidance is optimistic, with significant revenue growth expected. The positive sentiment is further supported by improved margins and cost optimization efforts, suggesting a favorable short-term stock price movement.
TOI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
